Peripheral artery disease (PAD) is common and associated with significant morbidity and mortality. Optimal medical management of PAD is required for each patient, irrespective of the decision regarding lower extremity revascularization. The goals include reducing cardiovascular morbidity and mortality and improving quality of life. The approach should consist of aggressive and individualized risk factor modification including smoking cessation, antiplatelet therapy, a statin, and an angiotensin-converting enzyme inhibitor. Exercise is critical for cardiovascular health and highly effective for improving claudication symptoms. Cilostazol may be considered for symptomatic treatment in certain patients. (J Vasc Surg 2017;66:275-80.) Peripheral artery disease (PAD) affects >8 million Americans.
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1 PAD negatively affects the quality and length of life among those affected. The goals of the medical treatment of PAD focus on two areas: helping patients "live longer" by reducing cardiovascular morbidity and mortality and helping patients "feel better" by improving quality of life. The cornerstones of the medical management of PAD include risk factor modification, medications, such as statins and antiplatelet therapy, and exercise. 2 In addition, cilostazol may be considered for treatment of claudication symptoms, although adverse side effects can be limiting.
RISK FACTOR MODIFICATION
Smoking cessation. The effect of smoking in PAD is enormous, both in scope and effect. Up to 80% of patients with PAD are current or former smokers. 3 The risk of death, myocardial infarction (MI), and amputation is reported to be higher with continued smoking. Smoking cessation in PAD patients may reduce disease progression and may increase walking distance. 4 Smoking after lower extremity bypass increases the risk of graft failure by at least threefold; however, smoking cessation may restore the patency rates to the level of nonsmokers. 5 The patient with claudication is often uniquely motivated to quit smoking after learning that (1) the leg symptoms could improve with smoking cessation, and (2) the disease will worsen with continued smoking. If the symptoms can improve with simply quitting smoking without any further medical or surgical intervention, then smoking cessation should always be the first step. 6 Varenicline (Chantix; Pfizer Inc, Mission, Kan) is the most effective medication on the market for smoking cessation. It is a partial agonist (it both agonizes and blocks) a-4-b-2 nicotinic acetylcholine receptors, and by doing so, relieves withdrawal symptoms and simultaneously prevents further nicotine binding, which then partially blocks the reinforcing effects of nicotine. 7 Varenicline is more effective than bupropion and more effective than nicotine replacement therapy. The United States Food and Drug Administration (FDA) recently removed the black-box warning for the psychiatric side effects of varenicline. The EAGLES (Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders) study (n ¼ 8144) showed no increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo. 8 The same study found varenicline was more effective than placebo, nicotine patch, and bupropion; bupropion and the nicotine patch were also more effective than placebo. 8 Originally, practitioners would tend not to prescribe varenicline until patients were "ready to quit," partly because the medication is to be started w1 week before the patient's proposed quit date. More recent evidence suggests that perhaps patients should be prescribed varenicline even if they are not immediately ready to quit because it will still increase smoking cessation rates. 9 Table I offers a basic approach to smoking cessation in the vascular patient. 10 The five "A's" of smoking cessation are Ask, Advise, Assess, Assist, and Arrange. For providers who prefer not to provide pharmacologic treatment or counseling, another approach is Ask, Advise, and Refer. Partnerships between vascular surgery and vascular medicine can help to achieve this goal. The most important message is that the benefits of smoking cessation greatly exceed any risks associated with pharmacologic treatment.
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Hypertension. Hypertension should be treated according to current published guidelines to lower the risk of cardiovascular events. Guidelines from the Eighth Joint National Committee advised a target blood pressure of <140/90 mm Hg if the patient has diabetes or chronic kidney disease or is aged <60 years. 11 Otherwise, the target from the Eighth Joint National Committee was <150/90 mm Hg. The more recent SPRINT (Systolic Blood Pressure Intervention Trial) study has led to a more aggressive approach to blood pressure lowering. 12 SPRINT compared the benefit of treatment of systolic blood pressure to a target of <120 mm Hg with treatment to <140 mm Hg among patients at high risk for cardiovascular events but without diabetes. The lower target resulted in lower rates of major cardiovascular events and death from any cause, although with an increased risk of adverse events. 12 The ideal target blood pressure for patients with atherosclerotic vascular disease remains an active topic of debate. Angiotensin-converting enzyme (ACE) inhibitors are an excellent choice for the treatment of hypertension in the setting of PAD and reduce cardiovascular risk beyond simply lowering blood pressure. The HOPE (Heart Outcomes Prevention Evaluation) study randomized 9297 high-risk patients (including 4051 patients with PAD) to ramipril (10 mg/d) vs placebo. 13 At a mean follow-up of 4.5 years, a relative risk reduction of 22% was seen in the ramipril group (14.0%) compared with the placebo group (17.5%) for the composite end-point of MI, stroke, or cardiovascular death. 13 A subset of the HOPE trial, the SECURE trial (Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E; n ¼ 732) showed a delay in the progression of carotid intimal medial thickness by carotid ultrasound imaging. 14 The ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) study demonstrated that telmisartan, an angiotensin-receptor blocker (ARB), was equivalent to ramipril in prevention of cardiovascular events, including in the subgroup of patients with PAD. 15 Thus, current guidelines support the use of ACE inhibitors or ARBs to reduce the risk of cardiovascular events in patients with lower extremity PAD.
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Of note, b-blockers are not contraindicated in PAD patients. A meta-analysis of 11 randomized trials showed that b-blockers do not adversely affect walking capacity or claudication symptoms. 16 However, b-blockers are not first-line for treatment of hypertension but are commonly used for other indications such as heart failure, atrial fibrillation, or secondary prevention after MI.
Diabetes. Diabetes is a major risk factor for PAD and increases the risk of poor outcomes among PAD patients. 17 Patients with diabetes and PAD require a comprehensive and multidisciplinary care plan to include nutrition, weight management, podiatry, ophthalmology, endocrinology, and medications for glycemic control. 1 For many years, the accepted target hemoglobin A 1c was <7%. Recently, the trend has shifted to a more individualized approach to glycemic control. For example, a more relaxed goal may be safer in older patients on insulin. Glycemic control has more effect on microvascular complications than on macrovascular complications and is particularly vital among patients with critical limb ischemia. 
MEDICATION
Statin therapy. All patients with PAD should be taking a statin, regardless of cholesterol levels.
1 This recommendation is based on the Heart Protection Study (n ¼ 20,536, of whom 6748 had PAD), which demonstrated a 22% relative risk reduction in the first major vascular event among PAD patients randomized to simvastatin (40 mg) vs placebo. 20 Patients with PAD qualify for high-intensity statin treatment based on current cholesterol guidelines, which means that the goal is lowering the low-density lipoprotein cholesterol (LDL-C) by at least 50%. 21 To achieve this degree of LDL-C lowering, the best options based on clinical trial data are atorvastatin (40 mg or 80 mg) or rosuvastatin (20 mg or 40 mg). Atorvastatin and rosuvastatin are similar. One study found that rosuvastatin (40 mg) had a more favorable effect on the lipid profile (with lower LDL-C and higher high-density lipoprotein cholesterol levels) compared with atorvastatin (80 mg), but a similar degree of regression of percent atheroma volume was seen in the coronary arteries. 22 Atorvastatin and rosuvastatin are generic; however, the cost to the patient may differ by formulary or prescription plan. Of note, the maximum daily dose of rosuvastatin is 10 mg if the creatinine clearance is <30 mL/min. Moderate-intensity statin treatment (lowering the LDL-C by w30% to <50%) can be considered for patients who are aged >75 years (eg, atorvastatin at 10 mg or 20 mg; rosuvastatin at 5 mg or 10 mg). 21 Simvastatin (20-40 mg) is another moderate-intensity option, but the FDA has issued restrictions. Simvastatin at 80 mg should be avoided altogether due to the risk of myopathy. Furthermore, the maximum daily dose of simvastatin is 20 mg when combined with amiodarone or with amlodipine, which is commonly prescribed for hypertension. In addition to reducing cardiovascular risk, a few small studies have reported that statins may also improve claudication symptoms. In one study (n ¼ 69), simvastatin (40 mg) increased pain-free treadmill walking time at 6 and 12 months compared with placebo. 23 In a larger study (n ¼ 354), atorvastatin (80 mg) also improved pain-free walking time at 12 months compared with placebo. 24 Statins also improve outcomes in patients with critical limb ischemia. 25 Statins receive considerable attention in the media, with various reports of increased risk of diabetes, muscle issues, and liver toxicity. Much of the current controversy surrounds the use of statins in primary prevention, which is not relevant to PAD patients. Patients with PAD are high risk and have established atherosclerotic vascular disease, in which case there is no debate about the statin benefits, which are enormous regardless of the cholesterol levels.
Given that PAD patients usually already have leg pain, the question of myalgias or statin-induced myopathy often arises among PAD patients. Adverse effects of statins are typically mild and reversible. Efficacy and adverse effects vary among all statins because of their different pharmacokinetic and pharmacodynamics properties. 26 Thus, if a patient reports muscle pains from one statin, then a lower dose of the same statin or an alternative statin should be prescribed. The cardiovascular benefits of statins greatly outweigh any risks in the PAD population.
Antiplatelet therapy. Aspirin (typically 81 mg/d; range, 75-325 mg/d) is recommended for the reduction of the risk of MI, ischemic stroke, and vascular death among patients with symptomatic PAD. 1 The data supporting this recommendation are derived from the Antiplatelet Trialists' Collaboration, a meta-analysis of 287 studies of 135,000 patients with cardiovascular disease, including 9214 patients with PAD. 27 In the PAD subgroup, there was a 23% odds reduction for serious vascular events. Subsequent studies have suggested that the benefits of antiplatelet therapy are greater among patients with symptomatic PAD and are somewhat controversial among patients with asymptomatic PAD. In general, aspirin is underprescribed in PAD patients compared with patients with coronary artery disease (CAD). Clopidogrel (75 mg/d) is an alternative to aspirin. It may be marginally more effective than aspirin based on the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) trial, although it is more costly. CAPRIE randomized 19,185 patients with recent MI, ischemic stroke, or symptomatic PAD to clopidogrel vs aspirin (325 mg). In the PAD subgroup (n ¼ 6452), a 23.8% relative risk reduction for vascular events was seen with clopidogrel compared with those treated with aspirin; however, the absolute risk reduction was small (1.15%).
Dual antiplatelet therapy (aspirin plus clopidogrel) is generally not needed in PAD patients, although it may be considered in patients who are extremely high risk. 29 For example, dual antiplatelet therapy may be reasonable for a high-risk patient with diabetes who smokes and has PAD with concomitant CAD, particularly for as long as the patient continues to smoke. Ticagrelor is an oral, reversible inhibitor of P2Y 12 with faster onset/offset than clopidogrel and more predictable inhibition of adenosine 5 0 -diphosphate-induced platelet aggregation. The recent EUCLID (A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease) trial found that ticagrelor (90 mg twice daily) was not superior to clopidogrel for the reduction of cardiovascular events among patients with symptomatic PAD and that major bleeding rates were similar. 30 In the WAVE (Warfarin Antiplatelet Vascular Evaluation) trial, the combination of anticoagulation with warfarin plus antiplatelet therapy was not more effective than antiplatelet therapy alone in preventing cardiovascular events; the combination was associated with an increase in lifethreatening bleeding. 31 Thus, there is no role for anticoagulation for PAD.
EXERCISE
Exercise plays a fundamental role in the treatment of PAD. It has been shown since the 1960s to be an effective treatment for claudication, leading to improvement in both pain-free and maximal walking distance. The CLEVER (Claudication: Exercise Vs Endoluminal Revascularization) trial found that a supervised exercise program improved treadmill walking performance more than endovascular revascularization for patients with aortoiliac disease. 32 A detailed discussion of exercise for PAD is provided in this supplement.
Current guidelines indicate that all patients should achieve 30 minutes of brisk exercise daily for overall cardiovascular health. This recommendation is especially important for PAD patients. Generally, patients should walk until they have moderate pain or discomfort (4 on a scale of 1 to 5), stop and rest until the pain subsides, and then start walking again. 32 Patients should aim to reach this moderate level of pain within the first 5 to 7 minutes of walking. Over time, they will need to walk uphill or more quickly, or both, to bring on the pain within this timeframe. These intermittent bouts of rest and exercise are thought to improve oxygen extraction by the muscles; claudication symptoms improve through a variety of mechanisms. 33 Exercise has tremendous benefits that extend far beyond the improvement in claudication symptoms and functional capacity and include improving endothelial function, blood pressure, cholesterol, glycemic control, and systemic cardiovascular health. 33 
PHARMACOLOGIC TREATMENT OF CLAUDICATION SYMPTOMS
Options are limited in the medications directed at ameliorating claudication symptoms. The first such medication was pentoxifylline (400 mg thrice daily with meals), which was approved by the FDA in 1984 based on small studies. Pentoxifylline is thought to reduce viscosity and improve erythrocyte flexibility; unfortunately, subsequent studies have shown that it is no different from placebo in treating claudication. 34 Pentoxifylline is thus not recommended for PAD patients. 1 Approved by the FDA in 1999, cilostazol is a phosphodiesterase III inhibitor and is more effective than pentoxifylline. 34 A Cochrane review of 15 double-blind, randomized controlled trials (n ¼ 3718) concluded that cilostazol improves walking distance among patients with claudication. Cilostazol is a vasodilator that inhibits vascular smooth muscle cell proliferation and prevents platelet aggregation. Its mechanism for improving claudication symptoms is not clear and is probably multifactorial. The dose is 100 mg twice daily and should be taken at least 30 minutes before or 2 hours after breakfast and dinner. Adverse effects can be limiting and include and ramipril (10 mg/d). These three medications are aimed at reducing cardiovascular morbidity and mortality, or to achieve the "live longer" goal. Given the high prevalence of diabetes and hypertension, the same PAD patient may also take other medications such as metformin, gabapentin, amlodipine, or hydrochlorothiazide. With this extensive medication list, the patient and the practitioner may be hesitant to add cilostazol considering its adverse effect profile and suboptimal efficacy. A 3-month course of medical management, including an exercise program, is a reasonable approach before adding cilostazol, which can be seen as an intermediate step before endovascular or surgical revascularization.
FUTURE DIRECTIONS
Future research in PAD will include further study of antithrombotic agents such as vorapaxar and ticagrelor and the direct oral anticoagulants such as rivaroxaban and apixaban. Vorapaxar is an oral, reversible antagonist of protease-activated receptor 1. When added to existing antiplatelet therapy, it reduced the risk of cardiovascular events among patients with atherosclerosis but at the expense of increased bleeding. 35 Cardiovascular events
were not reduced in the PAD subgroup; however, limbrelated events (acute limb ischemia) and peripheral revascularization were reduced, but with an increased risk of bleeding. 36 The clinical benefit of these newer medications remains uncertain.
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CONCLUSIONS
The medical management of PAD is aimed at the two goals of living longer and feeling better. For the "live longer" goal, mandatory medications include antiplatelet therapy, a statin, and an ACE inhibitor, as summarized in Table II . For the "feel better" goal, the main pharmacologic treatment is cilostazol. Fortunately, exercise is a safe and low-cost treatment option that achieves both aims. 
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